Welcome to our dedicated page for Healthcare Triangle news (Ticker: HCTI), a resource for investors and traders seeking the latest updates and insights on Healthcare Triangle stock.
Healthcare Triangle, Inc. reports developments in healthcare information technology, digital health platforms, cloud enablement, managed services, and data analytics for healthcare and life sciences organizations. Company news includes product and customer updates involving hospital information management, interoperability, telehealth, AI-powered clinical and operational automation, and customer-engagement tools.
Recurring HCTI updates also cover subsidiary activity at QuantumNexis, international expansion across Africa, the Middle East, and related healthcare markets, partnership and joint-venture activity, and capital-structure actions such as share repurchase authorization and reverse stock split disclosures.
Healthcare Triangle (Nasdaq: HCTI) signed a definitive agreement to acquire Spain-based AI CX assets run by Teyame AI, aiming to expand its SaaS footprint in Europe and Latin America.
The deal contemplates up to $50 million in total consideration (cash, common stock, non-voting convertible preferred stock, and contingent earnout equity), targets a closing on Jan 29, 2026 subject to shareholder approval, and is effective Jan 1, 2026 for accounting. The assets reported ~$32M revenue and ~$3.6M EBITDA for FY2025; the company forecasts incremental $38M NTM revenue and $5M NTM EBITDA.
Healthcare Triangle (Nasdaq: HCTI) signed an Advance Agreement to acquire Spain-based AI customer engagement Assets run by Teyame AI, targeting a closing in Q1 2026 subject to a definitive purchase agreement, due diligence, shareholder approval, and customary conditions. The contemplated deal values consideration at up to approximately $50 million in cash, common stock, non-voting convertible preferred stock and contingent earnouts. The company expects the Assets to generate ~$34 million incremental revenue and $4.2 million incremental EBITDA for fiscal year 2025, and to expand HCTI's AI-driven patient engagement and global SaaS strategy.
Healthcare Triangle (Nasdaq: HCTI) signed a non-binding Letter of Intent to acquire assets of Spain-based Teyame.AI, an AI-driven omnichannel customer experience platform. Based on information received, Teyame is expected to generate approximately $34 million in revenue and $4.2 million in EBITDA for fiscal 2025. The combination aims to create a global, AI-powered patient engagement platform by integrating Teyame's Agentic Gen AI, multilingual automation, and analytics with HCTI's clinical systems and QuantumNexis products.
Anticipated impacts include expanded international reach (Europe, LATAM, MENA, APAC), cross-selling into HCTI's hospital and clinic network, enhanced digital mental health workflows, and tighter front-end to back-end clinical integration. The LOI remains non-binding and subject to completion.
Healthcare Triangle (Nasdaq: HCTI) entered into warrant exercise agreements with certain accredited and institutional investors to immediately exercise an aggregate of 239,051 existing warrants for gross cash proceeds of approximately $478,000. The company agreed to reduce the existing warrant exercise price from $20.92 to $2.00 per share.
In a private placement, the exercising holders will receive new unregistered warrants to purchase up to 239,051 shares at an exercise price of $3.00 per share; the New Warrants are immediately exercisable and expire five years from issuance. The transactions and closing are expected on or about October 8, 2025. WallachBeth Capital acted as financial advisor.
Healthcare Triangle (Nasdaq: HCTI) announced on Oct 3, 2025 that holders agreed to immediately exercise outstanding warrants to buy 377,702 common shares for aggregate gross proceeds of approximately $755,000. In return, those holders will receive new unregistered warrants to purchase up to 377,702 shares at an exercise price of $3.00 per share.
The company reduced the exercise price of the Existing Warrants from $20.92 to $2.00. The New Warrants are immediately exercisable, expire five years from issuance, and the transactions are expected to close on or about Oct 6, 2025. WallachBeth Capital is acting as financial advisor. Gross proceeds exclude any future New Warrant exercises and will be reduced by advisor fees and transaction expenses.
Healthcare Triangle (NASDAQ:HCTI) has secured approximately $1.63 million in gross proceeds through warrant exercise agreements with three existing accredited investors. The agreement involves the immediate exercise of existing warrants to purchase 812,775 shares of common stock, with the exercise price reduced from $20.92 to $2.00 per share.
In exchange, investors will receive new unregistered warrants to purchase an additional 812,775 shares at $3.00 per share, exercisable upon stockholder approval and expiring five years thereafter. WallachBeth Capital is serving as the sole placement agent for this warrant inducement transaction, expected to close on October 2, 2025.
Healthcare Triangle (Nasdaq: HCTI) announced that its subsidiary QuantumNexis's Ezovion EMR platform has processed over $20 million in revenue from healthcare providers. The company projects this figure to reach $37 million within six months as it expands into India, Bangladesh, Saudi Arabia, and Malaysia.
QuantumNexis plans to launch a proprietary integrated payment gateway that will generate 0.05% (five basis points) of all revenue processed through the platform. The platform operates on a consumption-based model, enabling healthcare providers to digitize and manage their operations while creating a scalable revenue stream for HCTI through transaction-based fees.
Summary not available.
Summary not available.
Summary not available.